---
document_datetime: 2023-09-21 17:38:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/novonorm-epar-procedural-steps-taken-authorisation_en.pdf
document_name: novonorm-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.6948435
conversion_datetime: 2025-12-14 15:48:03.510202
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Novo  Nordisk  A/S  submitted  on  16  June  1997  an  application  for  Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for NovoNorm, through the centralised procedure. After agreement by the CPMP on 20 March 1997, this medicinal product was referred to Part B of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

W. van der Giesen

## Licensing status

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 25 July 1997.
- The Rapporteur's first assessment report 2 October 1997.  The  Co-rapporteur's  first  assessment  report  was  circulated  to  all  CPMP Members on 1 October 1997.
- During the meeting on 17-19 November the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the Company on 21 November 1997.
- The company submitted the responses to the consolidated list of questions on 12 January 1998.
- The Rapporteur circulated the joint response assessment report on the company's responses to the list of questions to all CPMP Members on 27 February 1997.
- The  company  submitted  further  response  to  issues related to cardiovascular safety on 23 February and 2 April 1998.
- During  the  CPMP  meeting  on  20  April  1998,  outstanding  issues  were  addressed  by  the applicant during a hearing before the CPMP.
- During the meeting on 21-23 April 1998 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for  granting  a Marketing Authorisation to NovoNorm on 22 April 1998.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission which adopted the corresponding Decisions on 17 August 1998.

Co-Rapporteur: J. Genoux-Hames